Industries
Advanced therapies
What changes this industry: bio-solutions with evidence, technologies, suppliers and open money.
What it replaces 0
No graded substitution linked yet.
Technologies 26
| Adenoviral vector gene therapy Replication-defective adenoviral vectors that deliver vaccine antigens and therapeutic genes at industrial scale — platform families validated in pandemic … | Therapeutics & platforms |
| Base editing Base editors (CBE/ABE) make single-nucleotide changes C·G→T·A and A·T→G·C without double-strand breaks — treating monogenic disease (sickle cell, … | Genome engineering |
| Bioproduction CDMO/CMO (biologics/ATMP/mRNA) Contract development and manufacturing organizations providing specialized infrastructure for advanced biopharmaceuticals. | Therapeutics & platforms |
| CAR-T cell therapy A patient's own T cells are collected, engineered with a chimeric antigen receptor (CAR) using a lentiviral vector, expanded and re-infused to kill cancer — an … | Therapeutics & platforms |
| Cold chain for cell & gene therapies Specialized courier and logistics networks that manage the temperature-controlled, chain-of-identity transport of autologous and allogeneic cell and gene … | Cleanroom & facilities |
| Epigenome editing Turning genes on or off by rewriting DNA methylation and histone marks with dCas9 fusion proteins or zinc fingers — no DNA sequence change, but an effect that … | Genome engineering |
| Exosome therapy & extracellular vesicles Cell-derived nanoscale vesicles (30-150 nm) used as native regenerative-medicine agents or engineered as biocompatible drug-delivery vehicles for RNA, protein … | Regenerative & personalized medicine |
| Geroscience & senolytics Selectively clearing senescent 'zombie' cells or suppressing their inflammatory secretome to treat age-related disease at its molecular root, rather than one … | Regenerative & personalized medicine |
| In-space organ bioprinting Bioprinting soft human tissue in orbit, where the absence of gravity-driven sedimentation lets low-viscosity bioinks hold shape without the scaffolds and … | Cross-sector intersections |
| In-vitro gametogenesis (IVG) & reproductive synbio Deriving functional human eggs and sperm entirely outside the body from reprogrammed stem cells, aimed at reversing absolute infertility and enabling … | Regenerative & personalized medicine |
| In-vivo gene therapy: AAV and lentiviral vectors One-time, potentially curative genetic medicines delivered by engineered adeno-associated and lentiviral vectors — eight FDA-approved in-vivo products since … | Therapeutics & platforms |
| Induced pluripotent stem cells (iPSC) Reprogramming adult cells into an embryonic-like, expandable stem state — the platform behind off-the-shelf NK cells, defined culture media and human-iPSC … | Regenerative & personalized medicine |
| mRNA / LNP manufacturing equipment The mixers, skids and continuous-flow reactors that bring an mRNA payload and a four-lipid ethanol blend together in microseconds to self-assemble 80–120 nm … | Fill-finish & packaging |
| mRNA platforms & LNP delivery Synthetic mRNA in lipid nanoparticles (60–100 nm) turns the cell into a bioreactor — from a vaccine platform to personalised cancer immunotherapy and in-vivo … | Therapeutics & platforms |
| NK-cell & CAR-NK therapy CAR-NK and NK-cell therapy — allogeneic, off-the-shelf effector cells with low toxicity (minimal CRS, no GVHD) against solid and haematological cancers; iPSC-NK … | Therapeutics & platforms |
| Nucleic acid therapeutics (oligonucleotides) Short synthetic oligonucleotides — siRNA and antisense — bind a target messenger RNA to silence or reprogram a disease gene, enabled by GalNAc liver targeting … | Therapeutics & platforms |
| Organ & tissue bioprinting Additive manufacturing of living cells and biomaterials to construct functional tissue models and transplantable organs. | Regenerative & personalized medicine |
| Partial epigenetic reprogramming Transient expression of Yamanaka reprogramming factors to reverse epigenetic markers of cellular aging without erasing cell identity — OSK gene therapy, … | Regenerative & personalized medicine |
| Personalized & regenerative medicine Gene and cell therapy platforms for rare monogenic and oncological diseases: AAV vectors, lentiviral HSC editing, ex vivo CRISPR (Casgevy) and in vivo CRISPR … | Regenerative & personalized medicine |
| Prime editing Search-and-replace genome editing with a Cas9 nickase fused to a reverse transcriptase and an extended pegRNA — writing all 12 base substitutions and small … | Genome engineering |
| RNA editing (ADAR) therapeutics Engineered oligonucleotides that recruit the cell's endogenous ADAR enzymes to rewrite a pathogenic adenosine to inosine on disease transcripts — a reversible, … | Therapeutics & platforms |
| Stem cell therapy for autoimmune disease Living mesenchymal stromal cells (MSC) or regulatory T cells (Treg) are infused to re-tolerise the immune system in autoimmune and inflammatory disease — an … | Therapeutics & platforms |
| TCR therapy (T-cell receptor engineered T cells) Patient T cells are engineered with a high-affinity T-cell receptor (TCR) that recognises a peptide-MHC complex inside a solid-tumour cell — an approved … | Therapeutics & platforms |
| TIL therapy (tumor-infiltrating lymphocytes) TIL therapy — autologous tumor-infiltrating T-cells with polyclonal specificity; the first approved drug Lifileucel (Amtagvi, Iovance, FDA 2024) is a … | Therapeutics & platforms |
| Universal allogeneic CAR-T Off-the-shelf CAR and NK cells edited from healthy donors - one manufacture, many patients. The table carries three vendors with ledger-backed dossiers; … | Therapeutics & platforms |
| Xenotransplantation Transplanting organs from multiplex gene-edited pigs into humans to address the chronic shortage of donor organs, now moving from expanded-access compassionate … | Regenerative & personalized medicine |
Opportunities 4
| Tender | Czechia – Immunosuppressive agents – Imunosupresivum, monoklonální protilátka s obsahovou látkou … Fakultní nemocnice Ostrava, Fakultní nemocnice Olomouc, Fakultní nemocnice Hradec Králové | Oct 13, 2026 6 days |
| Tender | Netherlands – Influenza vaccines – Trivalent Influenza Vaccines 2026 Rijksinstituut voor Volksgezondheid en Milieu (RIVM), RIVM | Oct 19, 2026 12 days |
| Grant | Circular innovative advanced materials: facilitating the transition from design to markets (RIA) (Innovative … European Commission | Feb 2, 2027 118 days |
| Grant | Textile circularity through advanced processing and manufacturing technologies and system approaches (IA) … European Commission | Feb 2, 2027 118 days |